Boston Scientific has received US Food and Drug Administration (FDA) 510(k) clearance for its Embold soft and packing coils, the company has announced in a press release. The coils are designed for use in a variety of embolization procedures.
These coils further strengthen Boston Scientific’s embolic portfolio by creating a single platform consisting of just three coils, which is designed to make it simpler for physicians to address a variety of different patient needs and anatomies, while also streamlining hospital inventory. The soft and packing coils complete the trio by building on the success of the Embold fibred coil, which launched last year and is currently available in the USA, Canada and Japan.
“The addition of the soft and packing coils now completes the Embold platform, and is expected to build upon the success we have already seen with the launch of our fibred coil last year,” said Peter Pattison, president, Interventional Oncology and Embolization, Boston Scientific. “With the full platform of Embold coils, along with our conformable embolic, Obsidio, we will be able to offer our customers a complementary and highly differentiated portfolio of embolics, enabling them to provide highly personalised care to address the unique needs of their patients.”
